Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neurofibrosarcoma 1Colorectal Neoplasms 1

Interventions

Doxorubicin 17Ifosfamide 12Radiotherapy 8pazopanib 5selinexor 4pembrolizumab 4Filgrastim 4pegfilgrastim 3Sirolimus 3Nivolumab 3Magnetic Resonance Spectroscopy 3Imatinib Mesylate 3Etoposide 3AZD 6244 3fludarabine phosphate 2brostallicin 2X-Rays 2Trabectedin 2Specimen Handling 2Sorafenib 2Radiation Dose Hypofractionation 2Radiation 2Diathermy 2Chemotherapy, Adjuvant 2Biopsy 2thymoglobulin 1temsirolimus 1tazemetostat 1sotigalimab 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neurofibrosarcoma × metarrestin × Clear all
NCT04222413 2026-04-24

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
116 enrolled
GastrointestinalSarcoma

Pancreatic Neoplasms, Colorectal Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡